The Helicobacter felis Mouse Model in Assessing Anti-Helicobacter Therapies and Gastric Mucosal Prostaglandin E₂ Levels

References

• Blaser M J. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis 1990; 161: 626–33
   PubMed Web of Science ®Google Scholar
• Nomura A, Stemmerman G N, Chyou P-H, Kato I, Perez-Perez G I, Blaser M J. Helicobacter pylori infection and gastric carcinoma in a population of Japanese-Americans in Hawaii. N Engl J Med 1991; 325: 1132–6
   PubMed Web of Science ®Google Scholar
• Parsonnet J, Friedman G D, Vandersteen D P, Chang Y, Vogelman J H, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127–31
   PubMed Web of Science ®Google Scholar
• Glupczynski Y, Burette A, De Koster E. Metronidazole resistance in Helicobacter pylori. Lancet 1990; 335: 976–7
   PubMed Web of Science ®Google Scholar
• Rautelin H, Seppälä K, Renkonen O-V, Vainio U, Kosunen T U. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother 1992; 36: 163–6
   PubMed Web of Science ®Google Scholar
• Borody T J, Cole P, Noonan S, Morgan A, Lenne J, Hyland L, et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust 1989; 151: 431–5
   PubMed Web of Science ®Google Scholar
• Graham D Y, Lew G M, Malaty H M, Evans D G, Evans D J, Klein P D, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493–6
   PubMed Web of Science ®Google Scholar
• Paster B J, Lee A, Fox J G, Dewhirst F E, Tordoff L A, Fraser G J, et al. Phylogeny of Helicobacter felis sp. nov., Helicobacter mustelae, and related bacteria. Int J Syst Bacteriol 1991; 4: 31–8
   Google Scholar
• Dick-Hegedus E, Lee A. Use of a mouse model to examine anti-Helicobacter pylori agents. Scand J Gastroenterol 1991; 26: 909–15
   PubMed Web of Science ®Google Scholar
• Rautelin H, Renkonen O-V, Kosunen T U. In vitro susceptibility of Helicobacter pylori to nitecapone. Eur J Clin Microbiol Infect Dis 1992; 11: 274–5
   PubMed Web of Science ®Google Scholar
• Salmela K S, Roine R P, Höök-Nikanne J, Kosunen T U, Salaspuro M. Effect of bismuth and nitecapone on Helicobacter pylori acetaldehyde production. Scand J Gastroenterol 1994; 29: 528–31
   PubMed Web of Science ®Google Scholar
• Piotrowski J, Slomiany A, Liu J, Fekete Z, Slomiany B L. Effect of nitecapone on the proteolytic and lipolytic activities of Helicobacter pylori. Biochem (Life Sci Adv) 1991; 10: 79–83
   Google Scholar
• Aho P A, Linden I-B. Role of gastric mucosal eicosanoid production in the cytoprotection induced by nitecapone. Scand J Gastroenterol 1992; 27: 134–8
   PubMed Web of Science ®Google Scholar
• Hawkey C J, Rampton D S. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment. Gastroenterology 1985; 89: 1162–88
   PubMed Web of Science ®Google Scholar
• Avunduk C, Suliman M, Gang D, Polakowski N, Eastwood G L. Gastroduodenal mucosal prostaglandin generation in patients with Helicobacter pylori before and after treatment with bismuth subsalicylate. Dig Dis Sci 1991; 36: 431–4
   PubMed Web of Science ®Google Scholar
• Taha A S, Boothman P, McLaughlin S, McKinlay A, Upadhyay R, Kelly R W, et al. Effect of Campylobacter pylori (CP) on gastric prostaglandin in patients with gastric ulcers and non-ulcer dyspepsia. Gut 1989; 30: A732
   Web of Science ®Google Scholar
• Taha A S, McKinlay A W, Upadhyay R, Kelly R, Russell R I. Prostaglandins and Campylobacter pylori. Lancet 1989; 2: 800–1
   PubMed Web of Science ®Google Scholar
• Goren A, Fotherby K J, Shorthouse M, Wight D GD, Hunter J O. A letter. Lancet 1989; 2: 212
   PubMedGoogle Scholar
• Cryer B, Faust T W, Goldschmiedt M, Redfern J S, Lee E, Feldman M. Gastric and duodenal mucosal prostaglandin concentrations in gastric or duodenal ulcer disease: relationship with demographics, environmental, and histological factors, including Helicobacter pylori. Am J Gastroenterol 1992; 87: 1747–54
   PubMed Web of Science ®Google Scholar
• Peskar B M, Lange K, Hoppe U, Peskar B A. Ethanol stimulates formation of leukotriene C4 in rat gastric mucosa. Prostaglandins 1986; 31: 283–93
   PubMed Web of Science ®Google Scholar
• Chen M, Lee A, Hazell S, Hu P, Li Y. Immunisation against gastric infection with Helicobacter species: first step in the prophylaxis of gastric cancer. Int J Med Microbiol Virol Parasitol Infect Dis 1993; 280: 155–65
   Google Scholar
• Goodwin C S, Marshall B J, Blincow E D, Wilson D H, Blackbourn S, Phillips M. Prevention of nitroimidazole resistance in Campylobacter pylori by co-administration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol 1988; 41: 207–10
   PubMed Web of Science ®Google Scholar
• Danon S J, O'Rourke J L, Moss N D, Lee A. The importance of local acid production in the distribution of Helicobacter felis in the mouse stomach. Gastroenterology 1995; 108: 1386–95
   PubMed Web of Science ®Google Scholar
• Axon A TR. The role of omeprazole and and antibiotic combinations in the eradication of Helicobacter pylori—an update. Scand J Gastroenterol 1994; 29(Suppl 205)31–7
   Web of Science ®Google Scholar
• Aho P, Linden I-B, Nissinen E, Pohto P. Gastric mucosal protection in the rat by OR-462, a novel COMT-inhibitor. Dig Dis Sci 1988; 33: 897
   PubMed Web of Science ®Google Scholar
• Aho P, Linden I-B, Nissinen E, Pohto P. Prevention of cysteamine-induced duodenal ulcers in rats by a COMT-inhibitor. Dig Dis Sci 1988; 33: 905
   Web of Science ®Google Scholar
• Konturek S J, Radecki T, Piastucki I, Brzozowski T, Drozdowicz D. Gastroprotection by colloidal bismuth subcitrate (De-Nol) and sucralfate. Role of endogenous prostaglandins. Gut 1987; 28: 201–5
   PubMed Web of Science ®Google Scholar